Human genetic polymorphisms affecting HIV-1 diseases

International Journal of Hematology

Volumn 84, Issue 1, 2006, Pages 12-17

  Shioda, Tatsuo ^a   Nakayama, Emi E ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

AIDS; Chemokine; Cytokine; HIV 1; SNP

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3G; CD45 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CYTOCHROME P450; GENE PRODUCT; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; RANTES; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BASE PAIRING; CHRONIC DISEASE; DISEASE COURSE; EXPOSURE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; HUMAN GENOME; HUMAN GENOME PROJECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; NONHUMAN; PHENOTYPE; REVIEW; SEROCONVERSION; SEXUAL BEHAVIOR; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; GENOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CHRONIC DISEASE; DISEASE PROGRESSION; GENOME, HUMAN; HIV SEROPOSITIVITY; HUMANS; POLYMORPHISM, GENETIC;

EID: 33748652705     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06100     Document Type: Review

References (48)

1. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
2. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
3. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273:1856-1862.
4. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCRS-Δ 32, CCR2-64I, and SDF-1 3′Aalleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782-795.
5. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 1998;351:14-18.
6. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 1998;4:350-353.
7. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998; 282:1907-1911.
8. Shioda T, Nakayama EE, Tanaka Y, et al. Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J Virol. 2001;75:3462-3468.
9. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997;277:959-965.
10. Louisirirotchanakul S, Liu H, Roongpisuthipong A, et al. Genetic analysis of HIV-1 discordant couples in Thailand: association of CCR2 64I homozygosity with HIV-1-negative status. J Acquir Immune Defic Syndr. 2002;29:314-315.
11. Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science. 2000;287:2274-2277.
12. Hendel H, Winkler C, An P, et al. Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism. J Acquir Immune Defic Syndr. 2001;26:507-511.
13. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998; 279:389-393.
14. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS. 1998;12:F85-F90.
15. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS. 2000;14:2671-2678.
16. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A. 2001;98:5199-5204.
17. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A. 2002;99:10002-10007.
18. Wichukchinda N, Nakayama EE, Rojanawiwat A, et al. Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS. 2006;20:189-196.
19. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A. 1999;96:4581-4585.
20. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434-1440.
21. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A. 2000;97:14467-14472.
22. Nakayama EE, Meyer L, Iwamoto A, et al. Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J Infect Dis. 2002;185:1183-1186.
23. Tchilian EZ, Wallace DL, Dawes R, et al. A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. AIDS. 2001;15:1892-1894.
24. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between K1R3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31:429-434.
25. An P, Bleiber G, Duggal P, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol. 2004;78:11070-11076.
26. Foster CB, Lehrnbecher T, Samuels S, et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood. 2000;96:2562-2567.
27. Miserez AR, Muller PY, Barella L, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS. 2001; 15:2045-2049.
28. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-α gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS. 2003;17:121-123.
29. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322-1326.
30. McNeil AJ, Yap PL, Gore SM, et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM. 1996;89:177-185.
31. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A. 2000;97:2709-2714.
32. Itescu S, Mathur-Wagh U, Skovron ML, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr. 1992;5:37-45.
33. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999; 283:1748-1752.
34. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med. 2003;9:928-935.
35. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
36. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121-1122.
37. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet. 1998;62:1507-1515.
38. Michael NL, Nelson JA, KewalRamani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32. J Virol. 1998;72:6040-6047.
39. Capoulade-Metay C, Ma L, Truong LX, et al. New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia. AIDS. 2004;18:2243-2252.
40. Mulherin SA, O'Brien TR, Ioannidis JP, et al. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS. 2003;17:377-387.
41. van Rij RP, de Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA, Schuitemaker H. Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis. 1998;178:1806-1811.
42. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS. 2004;18:729-738.
43. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866-870.
44. Salkowitz JR, Bruse SE, Meyerson H, et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol. 2003;108:234-240.
45. Tiensiwakul P. Stromal cell-derived factor (SDF) 1-3′A polymorphism may play a role in resistance to HIV-1 infection in seronegative high-risk Thais. Intervirology. 2004;47:87-92.
46. Liu H, Shioda T, Nagai Y, et al. Distribution of HIV-1 disease modifying regulated on activation normal T cell expressed and secreted haplotypes in Asian, African and Caucasian individuals. French ALT and IMMUNOCO Study Group. AIDS. 1999;13:2602-2603.
47. Gonzalez P, Alvarez R, Batalla A, et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2001;2:191-195.
48. Abdi R, Tran TB, Sahagun-Ruiz A, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol. 2002;13:754-758.